|
Hyperuricemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Dotinurad, a novel selective urate reabsorption inhibitor, exerts a serum uric acid-lowering effect by selectively inhibiting urate transporter 1 (URAT1) in patients with hyperuricemia.
|
31823130 |
2020 |
|
Hyperuricemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Dotinurad is indicated for patients with hyperuricemia/gout as most patients with hyperuricemia are classified into "underexcretion type", which requires the inhibition of URAT-1 to excrete excess UA via the kidney.
|
31754883 |
2020 |
|
Hyperuricemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Dotinurad, a novel selective urate reabsorption inhibitor (SURI), reduces serum uric acid levels by selectively inhibiting urate transporter 1 (URAT1) for the treatment of hyperuricemia with or without gout.
|
31792640 |
2020 |
|
Hyperuricemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
The urate transporter-1 (URAT1) is crucial in developing hyperuricemia via reabsorption of uric acid in renal tubules, and its function is regulated by several single nucleotide polymorphisms (SNPs) within SLC22A12 gene encoding URAT1.
|
31478104 |
2019 |
|
Hyperuricemia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
To identify potential causative mutations in SLC2A9 and SLC22A12 that lead to hypouricemia or hyperuricemia (HUA).
|
31131560 |
2019 |
|
Hyperuricemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
The inhibitor of uric acid reabsorptive transporter URAT1 in kidney is drawing attention as a drug target for hyperuricemia.
|
30826184 |
2019 |
|
Hyperuricemia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
CAGM and its modified formulation significantly ameliorated PO-induced hyperuricemia in mice, which might be partially attributable to reductions of hepatic XOD and renal URAT1 levels.
|
30832523 |
2019 |
|
Hyperuricemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Synthesis, biological evaluation and 3D-QSAR studies of 1,2,4-triazole-5-substituted carboxylic acid bioisosteres as uric acid transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia associated with gout.
|
30579795 |
2019 |
|
Hyperuricemia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
About 90% of patients develop hyperuricemia due to insufficient urate excretion; thus, it is important to develop URAT1 inhibitors that could enhance renal urate excretion by blocking the reabsorption of urate anion.
|
31593642 |
2019 |
|
Hyperuricemia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we found the significant decrease in protein expression of URAT1 and GLUT9, and the significant increase in protein expression of OAT1 in the kidney in AFPR treated groups compared to the model groups of hyperuricemia.
|
29490297 |
2018 |
|
Hyperuricemia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We observed that the two flavones possess potent effect in hyperuricemia mice by decreasing the level of mURAT1 and inhibiting XO activity, which contribute to enhancing uric acid (UA) excretion and improving hyperuricemia-induced renal dysfunction.
|
29519319 |
2018 |
|
Hyperuricemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Research on the pharmacodynamics and mechanism of Fraxini Cortex on hyperuricemia based on the regulation of URAT1 and GLUT9.
|
29990831 |
2018 |
|
Hyperuricemia
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
|
Hyperuricemia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Moreover, serum and hepatic XOD activities and renal URAT1 expression declined in J99745-treated hyperuricemia mice.
|
29719791 |
2018 |
|
Hyperuricemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Verinurad (RDEA3170) is a high-affinity inhibitor of the URAT1 transporter in clinical development for treating gout and asymptomatic hyperuricaemia.
|
29868853 |
2018 |
|
Hyperuricemia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The expression of URAT1 was returned to normal, resulting in an increase of renal urate excretion and consequent healing of adenine-induced hyperuricemia in mice.
|
30486413 |
2018 |
|
Hyperuricemia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Prevalence of hyperuricemia among the Chinese population of the southeast coastal region and association with single nucleotide polymorphisms in urate‑anion exchanger genes: SLC22A12, ABCG2 and SLC2A9.
|
30015934 |
2018 |
|
Hyperuricemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
We screened the inhibitory potential of these crude drugs against urate transporter 1 (URAT1) to discover new drugs for hyperuricemia.
|
30388753 |
2018 |
|
Hyperuricemia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The correlation between rs3825016 polymorphism of SLC22A12 and hyperuricaemia susceptibility is possible.
|
29352852 |
2018 |
|
Hyperuricemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
This study aimed to investigate effects of BDEO on XOD and URAT1 in vitro, as well as the possible mechanism by which BDEO attenuated hyperuricemia in vivo.
|
27951420 |
2017 |
|
Hyperuricemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Discovery of Flexible Naphthyltriazolylmethane-based Thioacetic Acids as Highly Active Uric Acid Transporter 1 (URAT1) Inhibitors for the Treatment of Hyperuricemia of Gout.
|
27633583 |
2017 |
|
Hyperuricemia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Resveratrol contributes to URAT1 expression, which is potentially useful in therapeutic strategies aimed at treating hyperuricemia.
|
28499081 |
2017 |
|
Hyperuricemia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
G. pensylvanicum extract showed activity in reducing serum uric acid (Sur) through effect renal glucose transporter 9 (GLUT9), organic anion transporter 1 (OAT1) and urate transporter 1 (URAT1) mainly and inhibited XO activity in vivo of mice with PO induced hyperuricemia.
|
28623927 |
2017 |
|
Hyperuricemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
GAE and GAW downregulated the level of CNT2 proteins in the gastrointestinal tract of hyperuricemia mice.Thus, <i>G. applanatum</i> produced outstanding hypouricemic effects, mediated by renal OAT1, GLUT9, and URAT1 and gastrointestinal CNT2 that might elevate urine uric secretions and decline in the absorption of purine in the gastrointestinal tracts.<i>G. applanatum</i> showed little negative influence on inner organs.
|
29379442 |
2017 |
|
Hyperuricemia
|
0.200 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS GPS may be an effective treatment for hyperuricemia via a decrease in xanthine oxidoreductase through the XOD/XDH system; and via an increase in urate excretion through regulating URAT1, GLUT9, and OAT1 transporters.
|
28258276 |
2017 |